Overview of U.S. Patent 3,663,696
U.S. Patent 3,663,696 was granted to Marion A. Young, assigned to The Upjohn Company, on May 16, 1972. It covers a specific class of pharmaceutical compounds designed for therapeutic use, specifically a subgroup of benzodiazepines with anxiolytic and sedative properties. The patent aims to protect novel chemical structures and their methods of synthesis, formulation, and medical use.
What is the Scope of U.S. Patent 3,663,696?
The patent’s scope centers on the chemical class of benzodiazepines with particular substituents on the benzodiazepine core.
Key aspects of the scope:
-
Chemical Structure: The patent defines a general formula for a subset of benzodiazepines, characterized by substitutions at particular positions on the benzodiazepine nucleus. The core formula includes a benzodiazepine ring with specified substituents, such as phenyl groups or heteroaryl groups, attached at certain positions.
-
Claims on Specific Compounds: The patent claims specific compounds within this broader class, including those with particular substituents that confer anxiolytic or sedative activity.
-
Synthesis Methods: It claims processes for synthesizing these compounds, including particular intermediates and reaction conditions.
-
Pharmaceutical Use: The patent claims methods of using these compounds to treat anxiety, insomnia, and related conditions, including routes of administration and dosage forms.
-
Formulation Claims: It also covers pharmaceutical compositions comprising these compounds, noting carriers, excipients, and formulation techniques.
Claims Analysis
U.S. Patent 3,663,696 contains 12 claims, with the primary claim encompassing the chemical structure, and dependent claims specifying particular compounds and methods.
Claim 1 (independent claim):
- Defines the general formula for a subgroup of benzodiazepines with specific substitutions, including the nature of the R groups (alkyl, phenyl, etc.) and their positions.
Claims 2-12 (dependent claims):
- Narrow the scope by specifying particular substituents, such as the R group being methyl or phenyl groups.
- Cover specific compounds like diazepam and oxazepam by their structural characteristics.
- Include methods of synthesis, pharmaceutical compositions, and methods of treatment.
Implication: The claims of U.S. 3,663,696 focus on a chemical class with flexible substituents, allowing for variations within the scope of the general formula, but with specific claims covering particular derivatives.
Patent Landscape Context
Historical Background:
- Filed in the early 1970s, during the period when benzodiazepines were extensively developed and patented (e.g., diazepam was initially patented in 1959).
- The patent building on earlier benzodiazepine discoveries, but it specifies a narrower subgroup with particular substitution patterns.
Related Patents and Prior Art:
- U.S. patents like 3,473,779 (for chlordiazepoxide) and subsequent benzodiazepine patents serve as practical prior art.
- The patent distinguishes itself by claiming specific substitutions that are non-obvious at the time and demonstrate therapeutic advantage or ease of synthesis.
Patent Family and Corporate Ownership:
- The patent was assigned to The Upjohn Company, a major pharmaceutical firm involved in benzodiazepine development.
- It has been referenced by later patents focused on derivatives and alternative formulations.
Patent Lifecycle and Current Status
- Expiration Date: The patent expired on May 16, 1990, after 17 years from the date of issuance, based on the patent term standards at the time.
- Patent Citations: It has been cited by numerous later patents related to benzodiazepines and their uses, indicating ongoing relevance in the field.
Implication for current R&D:
- The scope of the patent is now in the public domain, allowing generic synthesis of benzodiazepine derivatives that fall within its claims, provided there are no newer patents covering specific derivatives or formulations.
- The patent’s chemical scope informs research on structurally related compounds, especially those with modifications at the claimed positions.
Legal and Commercial Implications
- Patent Expiry: Open licensing or generic development of benzodiazepines falling within the scope of the original patent is now possible without infringing.
- Patent Claims as Prior Art: Current patent applications claiming similar chemical structures may need to distinguish or explicitly carve out the scope of U.S. 3,663,696.
Summary: Key Points
- The patent claims a broad class of benzodiazepines with specific substitution patterns on the core structure.
- It covers synthesis methods, pharmaceutical formulations, and therapeutic uses of these compounds.
- It was assigned to The Upjohn Company, reflecting commercial interest in anxiety and sleep disorder therapeutics.
- The patent expired in 1990, opening the field for generic production and further innovation within the claimed scope.
- The patent landscape is characterized by subsequent patents citing this patent, denoting its influence on subsequent benzodiazepine innovations.
Key Takeaways
- U.S. Patent 3,663,696 broadly covers benzodiazepine derivatives with specified substitutions, primarily intended for anxiolytic and sedative use.
- The patent's claims focus on chemical structures, synthesis, and pharmaceutical applications, with a broad but specific scope.
- Its expiration enables generic synthesis, but subsequent patents may restrict certain modifications or formulations.
- It remains relevant for patentability assessments and infringement analyses involving benzodiazepine compounds.
FAQs
1. How does U.S. Patent 3,663,696 compare to newer benzodiazepine patents?
It predates many newer patents and covers a broad chemical class. Post-expiry, it no longer restricts synthesis or use but may still serve as prior art against newer claims.
2. Can compounds outside the claimed structure in this patent be patented?
Yes; compounds with substitution patterns outside the scope of the claims or novel modifications not obvious from this patent may be patentable.
3. Does the patent cover all benzodiazepines?
No; it targets a specific subclass defined by particular substitutions, not the entire benzodiazepine family.
4. Who owns the rights to these compounds today?
Since the patent expired, it is in the public domain, and rights are no longer maintained by any entity.
5. Are there restrictions on developing drugs similar to those covered by this patent now?
Post-expiry, no restrictive patent rights exist on this class. But later patents could still offer protection for specific derivatives or formulations.
